We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 06, 2020

Targeting β2-Adrenergic Receptors Shows Therapeutic Benefits in ccRCC From VHL Disease

Journal of Clinical Medicine


Additional Info

Journal of Clinical Medicine
Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma From Von Hippel-Lindau Disease
J Clin Med 2020 Aug 25;[EPub Ahead of Print], V Albiñana, E Gallardo-Vara, I de Rojas-P, L Recio-Poveda, T Aguado, A Canto-Cano, DT Aguirre, MM Serra, P González-Peramato, L Martínez-Piñeiro, AM Cuesta, LM Botella

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading